Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.52 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.48 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.44 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.44 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.44 |
| ▸ | GRIA3 | P42263 | 2/20 | 0.44 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.44 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.44 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.44 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13617483 | 0.80 | ERCC1 (0.53) | KDM4EALDH1A1GLAERCC1ERCC4 | |
| SCHEMBL3293088 | 0.78 | ALDH1A1 (0.63) | KDM4EALDH1A1GLACYP1A2CYP3A4 | |
| SCHEMBL458846 | 0.76 | KDM4E (0.61) | KDM4EALDH1A1GLACYP1A2CYP3A4 | |
| SCHEMBL3863268 | 0.76 | KDM4E (0.61) | KDM4EALDH1A1GLACYP1A2CYP3A4 | |
| SCHEMBL4544154 | 0.76 | KDM4E (1.00) | KDM4EALDH1A1GLACYP1A2CYP3A4 | |
| SCHEMBL5137768 | 0.76 | KDM4E (0.61) | KDM4EALDH1A1GLACYP1A2CYP3A4 | |
| SCHEMBL4057148 | 0.72 | KDM4E (0.61) | KDM4EALDH1A1GLACYP1A2CYP3A4 | |
| SCHEMBL20945207 | 0.72 | KDM4E (0.61) | KDM4EALDH1A1GLACYP1A2CYP3A4 | |
| SCHEMBL6249816 | 0.72 | KDM4E (0.61) | KDM4EALDH1A1GLACYP1A2CYP3A4 | |
| SCHEMBL4912309 | 0.72 | KDM4E (0.56) | KDM4EALDH1A1GRIA1GRIA2GRIA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4267574-B1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS INC (US) | 2025-04-23 | — | — | EP | disclosed |
| US-12043632-B2 | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors | AJAX THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| EP-4267574-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. (US) | 2023-11-01 | — | — | EP | disclosed |
| US-20230265075-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. | 2023-08-24 | — | — | US | disclosed |
| US-11691963-B2 | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors | AJAX THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-20230099203-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. | 2023-03-30 | — | — | US | disclosed |
| WO-2023009712-A1 | HETEROARYLOXY THIAZOLO AZINES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. (US) | 2023-02-02 | — | — | WO | disclosed |
| WO-2023009709-A1 | PYRAZOLO PIPERAZINES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. (US) | 2023-02-02 | — | — | WO | disclosed |
| WO-2022140527-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| US-20220017486-A1 | DOCK1-INHIBITING COMPOUND AND USE THEREOF | KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) | 2022-01-20 | — | — | US | disclosed |
| EP-1994011-B1 | SULFONYL BENZIMIDAZOLE DERIVATIVES | RAQUALIA PHARMA INC (JP) | 2010-10-13 | — | — | EP | disclosed |
| US-20100197679-A1 | COMPOUNDS | GLAXO GROUP LIMITED | 2010-08-05 | — | — | US | disclosed |
| US-7700618-B2 | Sulfonyl benzimidazole derivatives | PFIZER INC (US) | 2010-04-20 | — | — | US | disclosed |
| EP-2139898-A1 | COMPOUNDS | Glaxo Group Limited (GB) | 2010-01-06 | — | — | EP | disclosed |
| US-7598393-B2 | Sulfonyl benzimidazole derivatives | PFIZER INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-20090137584-A1 | SULFONYL BENZIMIDAZOLE DERIVATIVES | RAQUALIA PHARMA INC. (JP) | 2009-05-28 | — | — | US | disclosed |
| EP-1809607-B1 | SULFONYL BENZIMIDAZOLE DERIVATIVES | PFIZER (US) | 2008-12-17 | — | — | EP | disclosed |
| WO-2008128961-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-10-30 | — | — | WO | disclosed |
| US-20060094750-A1 | Sulfonyl benzimidazole derivatives | KON-I KANA | 2006-05-04 | — | — | US | disclosed |
| WO-1998045267-A1 | AMINOPYRIDINE DERIVATIVES FOR INFLAMMATORY AND MALIGNANT DISEASES | FERRING B.V. (NL) | 1998-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137584-A1 | SULFONYL BENZIMIDAZOLE DERIVATIVES | TRPV1, CNR2, CNR1 | KDM4E 4638/4885ALDH1A1 3471/4885GLA 2925/4885 |
| US-20230099203-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | JAK2, JAK3, STAT5B | KDM4E 444/4885ALDH1A1 3735/4885GLA 4663/4885 |
| US-20100197679-A1 | COMPOUNDS | NRDC, MRPL21, NISCH | KDM4E 4262/4885ALDH1A1 4306/4885GLA 1164/4885 |
| US-20230265075-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | JAK2, JAK3, STAT5B | KDM4E 444/4885ALDH1A1 3735/4885GLA 4663/4885 |
| US-12043632-B2 | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors | JAK2, JAK3, STAT5B | KDM4E 444/4885ALDH1A1 3735/4885GLA 4663/4885 |
| US-20220017486-A1 | DOCK1-INHIBITING COMPOUND AND USE THEREOF | DOCK2, DOCK11, DOCK5 | KDM4E 1951/4885ALDH1A1 217/4885GLA 4581/4885 |
| US-20060094750-A1 | Sulfonyl benzimidazole derivatives | TRPV1, CNR2, CNR1 | KDM4E 4614/4885ALDH1A1 2810/4885GLA 2274/4885 |
| US-11691963-B2 | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors | JAK2, JAK3, STAT5B | KDM4E 444/4885ALDH1A1 3735/4885GLA 4663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.